Vaccines with adjuvants. Preclinical studies
2018
Zh. I. Avdeeva | N. A. Alpatova | V. P. Bondarev | R. A. Volkova | N. I. Lonskaya | E. V. Lebedinskaya | N. V. Medunitsyn | A. N. Mironov | N. A. Ozeretskovsky | A. A. Soldatov | V. A. Shevtsov
The paper presents the data on safety and efficacy assessment of adjuvants and vaccines with adjuvants at the stages of development and preclinical studies based on international recommendations. The presence of an adjuvant in vaccine content ensures higher expressing and prolonged specific immunity. The origin and nature of adjuvants currently used for various vaccines are different. Adjuvants can be classified by origin, mechanism of action, physical and chemical properties. The finished vaccine may contain one or more adjuvants which can be intended for one antigen or a number of antigens in vaccine content. Antigen-adjuvant combination is a key part in the production of a vaccine with an adjuvant. Due to the diversity of adjuvant nature and their physical and chemical properties and mechanisms of action, as well as to antigens in adjuvant vaccines content, it is rather complicated to plan and to conduct preclinical studies. The present article describes various aspects of preclinical studies of adjuvants and vaccines with adjuvants based on the analysis of current guidelines and requirements.
显示更多 [+] 显示较少 [-]